- Home
- PRFX vs ENVB Comparison
PRFX vs ENVB Comparison
Compare PRFX & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRFX
- ENVB
- Stock Information
- Founded
- PRFX 2007
- ENVB 1994
- Country
- PRFX Israel
- ENVB United States
- Employees
- PRFX N/A
- ENVB N/A
- Industry
- PRFX Biotechnology: Pharmaceutical Preparations
- ENVB Biotechnology: Pharmaceutical Preparations
- Sector
- PRFX Health Care
- ENVB Health Care
- Exchange
- PRFX Nasdaq
- ENVB Nasdaq
- Market Cap
- PRFX 3.3M
- ENVB 2.7M
- IPO Year
- PRFX 2020
- ENVB N/A
- Fundamental
- Price
- PRFX $1.63
- ENVB $1.01
- Analyst Decision
- PRFX Hold
- ENVB Strong Buy
- Analyst Count
- PRFX 1
- ENVB 1
- Target Price
- PRFX N/A
- ENVB $10.00
- AVG Volume (30 Days)
- PRFX 8.7M
- ENVB 312.6K
- Earning Date
- PRFX 09-16-2025
- ENVB 08-14-2025
- Dividend Yield
- PRFX N/A
- ENVB N/A
- EPS Growth
- PRFX N/A
- ENVB N/A
- EPS
- PRFX N/A
- ENVB N/A
- Revenue
- PRFX N/A
- ENVB N/A
- Revenue This Year
- PRFX N/A
- ENVB N/A
- Revenue Next Year
- PRFX N/A
- ENVB N/A
- P/E Ratio
- PRFX N/A
- ENVB N/A
- Revenue Growth
- PRFX N/A
- ENVB N/A
- 52 Week Low
- PRFX $1.25
- ENVB $1.00
- 52 Week High
- PRFX $16.63
- ENVB $8.40
- Technical
- Relative Strength Index (RSI)
- PRFX 53.13
- ENVB 37.56
- Support Level
- PRFX $1.34
- ENVB $1.10
- Resistance Level
- PRFX $1.92
- ENVB $1.47
- Average True Range (ATR)
- PRFX 0.27
- ENVB 0.10
- MACD
- PRFX -0.02
- ENVB -0.02
- Stochastic Oscillator
- PRFX 13.05
- ENVB 2.13
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.